Laura A Johnson

List of Publications by Year
in descending order

33 papers	6,786 citations	257101 24 h-index	454577 30 g-index
33 all docs	33 docs citations	33 times ranked	9601 citing authors

#	Article	IF	Citations
1	Tumor antigenâ€“specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 2009, 114, 1537-1544.	0.6	1,481
2	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114, 535-546.	0.6	1,280
3	Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity, 2016, 44, 1444-1454.	6.6	458
4	Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity. Cancer Immunology Research, 2014, 2, 154-166.	1.6	448
5	Rational development and characterization of humanized antiâ€“EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine, 2015, 7, 275ra22.	5.8	369
6	Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions. Journal of Immunology, 2008, 180, 6116-6131.	0.4	319
7	Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes. Journal of Immunology, 2006, 177, 6548-6559.	0.4	287
8	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 2011, 117, 808-814.	0.6	272
9	Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma. Human Gene Therapy, 2012, 23, 1043-1053.	1.4	266
10	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clinical Cancer Research, 2014, 20, 972-984.	3.2	254
11	Driving gene-engineered T cell immunotherapy of cancer. Cell Research, 2017, 27, 38-58.	5.7	232
12	T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6973-6978.	3.3	203
13	Checkpoint Blockade Reverses Anergy in IL-13RÎ±2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. Molecular Therapy - Oncolytics, 2018, 11, 20-38.	2.0	123
14	Engineered T cells for cancer therapy. Cancer Immunology, Immunotherapy, 2014, 63, 969-975.	2.0	105
15	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. PLoS ONE, 2014, 9, e94281.	1.1	99
16	Structures of MART-126/27â€“35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition. Journal of Molecular Biology, 2007, 372, 1123-1136.	2.0	90
17	Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma. Ophthalmology, 2009, 116, 981-989.e1.	2.5	88
18	Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. Clinical Cancer Research, 2014, 20, 2684-2694.	3.2	74

#	Article	IF	Citations
19	2<scp>D TCR</scp>â€"p<scp>MHC</scp>â€"<scp>CD</scp>8 kinetics determines <scp>T</scp>â€cell responses in a selfâ€antigenâ€specific <scp>TCR</scp> system. European Journal of Immunology, 2014, 44, 239-250.	1.6	57
20	Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE, 2013, 8, e59082.	1.1	56
21	Immunotherapy Approaches for Malignant Glioma From 2007 to 2009. Current Neurology and Neuroscience Reports, 2010, 10, 259-266.	2.0	41
22	Specific Increase in Potency via Structure-Based Design of a TCR. Journal of Immunology, 2014, 193, 2587-2599.	0.4	39
23	Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunology, Immunotherapy, 2010, 59, 1551-1560.	2.0	35
24	Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. Journal of Immunological Methods, 2013, 392, 1-11.	0.6	28
25	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. Journal of Neuro-Oncology, 2015, 125, 65-74.	1.4	22
26	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology, 2013, 9, 977-990.	1.1	21
27	Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles Using a â€œModifiedâ€•Step-Filtration Process for Clearance of Packaging Cells. Human Gene Therapy, 2011, 22, 107-115.	1.4	18
28	Molecular imaging biomarkers for cell-based immunotherapies. Journal of Translational Medicine, 2017, 15, 140.	1.8	11
29	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. OncoImmunology, 2014, 3, e944059.	2.1	8
30	Model T Muscle CARs Can Treat Brain Tumors. Clinical Cancer Research, 2012, 18, 5834-5836.	3.2	2
31	Engineering the immune response to "self" for effective cancer immunotherapy. , 2014, 2, P22.		0
32	Toward Engineered Cells as Transformational and Broadly Available Medicines for the Treatment of Cancer. , 2018, , 695-717.		0
33	Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia. Blood, 2014, 124, 4803-4803.	0.6	0